EuroPCR 2023 | New Renal Denervation Devices Show Promising Results

The Netrod System study included 205 patients with uncontrolled essential hypertension while taking two drugs (nifedipine and hydrochlorothiazide), who were randomized 2:1 to denervation or sham control. All subjects had undergone renal angiography before randomization.

Renal denervation was done using the Setrod System device.

Mean patient age was 50 years old, and 16% of subjects were female.

In-office blood pressure was about 161/100 mmHg, and 152/96 mmHg during the 24-hour outpatient monitoring.

Those who underwent renal denervation more frequently reached the target blood pressure, 140/90 mmHg (64.7% vs. 7.7%; p = <0.0001), and a reduction of at least 5 mmHg in systolic blood pressure in the office setting (93.4% vs. 60%; p ≤ 0.0001).

Denervation-related complications were few. Only one patient presented a renal artery dissection, but it was related to catheterization.

Read also: EuroPCR 2023 | More Evidence in Favor of Renal Denervation.

Authors conclude that denervation with the Netrod System is safe and effective in patients with essential hypertension.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Reference: The Netrod System, presentado por el Dr. Fei Gao en el Congreso EuroPCR 2023, realizado en París, Francia.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...